Proactive Investors - Run By Investors For Investors

Summit Therapeutics expands drug pipeline with antibiotics targeting deadly bacteria

The DDS-04 series provides us with a major opportunity to improve patient outcomes across several body sites where Enterobacteriaceae cause infection,” said Dr David Roblin, president of research and development of Summit
Summit
Summit will present data on the antibiotics in Amsterdam next week

Summit Therapeutics PLC (LON:SUMM) is set to expand its drug portfolio with a new antibiotics series designed to fight bacteria responsible for infections of the bloodstream, lungs and urinary tract.

The company plans to present data on the series of new mechanism antibiotics, called DDS-04, at the 29th European Congress of Clinical Microbiology & Infectious Diseases in Amsterdam on April 13-16.

READ: Summit Therapeutics well backed for next phase of development

The DDS-04 series targets Enterobacteriaceae, a family of Gram-negative bacteria that includes Klebsiella pneumoniae and Escherichia coli, which can cause severe and often deadly infections.

Summit said DDS-04 has shown activity across a panel of K.pneumoniae and E. coli strains, including strains resistant to the antibiotics currently available. 

“The DDS-04 series provides us with a major opportunity to improve patient outcomes across several body sites where Enterobacteriaceae cause infection,” said Dr David Roblin, president of research and development of Summit. 

“We look forward to developing the programme to show compelling clinical and economic data that offer significant advantages over standard of care for the patients in need.”

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

man with erectile dysfunction
April 26 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use